IV Medications Elsevier

#1 IV Drug Handbook - 50 years

Veröffentlicht von: Skyscape Medpresso

Beschreibung

"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.
Use the #1 IV drug handbook to safely administer more than 400 intravenous drugs! Includes the most recent IV drugs to be approved by the FDA
Find the essential information you need to safely administer more than 400 intravenous drugs! For nearly 50 years, Elsevier’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2024 edition are 8 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
KEY FEATURES
- Detailed monographs on more than 400 IV drugs provide an impressive breadth of coverage that goes well beyond any comparable drug reference.
- Individual monographs include the drug name, phonetic pronunciation, usual dose, dilution, compatibility, rate of administration, actions, indications and uses, contraindications, precautions, interactions, side effects, antidote, and more.
- Additional drug monographs are provided on the Evolve website.
- Highlighted Black Box Warnings make it easy to locate information on medications with serious safety risks.
- Blue-screened text calls attention to special circumstances not covered by Black Box Warnings.
- Dosage and dilution charts within monographs provide quick summaries of essential clinical information.
- Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients.
- Convenient, A-to-Z format organizes all drug monographs by generic name, allowing you to find any drug in seconds.
Content licensed from printed edition ISBN-10: 0443121109
Content licensed from printed edition ISBN-13: 9780443121104
SUBSCRIPTION :
Please purchase a yearly auto-renewing subscription to receive content access and available updates.
Yearly auto-renewing payments- $49.99
Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.
If you have any questions or comments, email us any time: [email protected] or call 508-299-3000
Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx
Author(s):Shelly Rainforth Collins, PharmD
Publisher:Elsevier Health Sciences
Ausblenden Mehr anzeigen...

In-App-Käufe

Intravenous Medications 2022
$999.00
Elsevier IV Med HBK 1Y Sub off
$939.00
Elsevier’s IV Med HBK 1Y Sub
$1,159.00
Elsevier’s IV Med HBK 6M Sub
$759.00
Elsevier’s IV Med HBK 3/M Sub
$599.00

Screenshots

IV Medications Elsevier Häufige Fragen

  • Ist IV Medications Elsevier kostenlos?

    Ja, IV Medications Elsevier ist kostenlos herunterzuladen, enthält jedoch In-App-Käufe oder Abonnements.

  • Ist IV Medications Elsevier seriös?

    Nicht genügend Bewertungen, um eine zuverlässige Einschätzung vorzunehmen. Die App benötigt mehr Nutzerfeedback.

    Danke für die Stimme

  • Wie viel kostet IV Medications Elsevier?

    IV Medications Elsevier bietet mehrere In-App-Käufe/Abonnements, der durchschnittliche In-App-Preis beträgt $891.00.

  • Wie hoch ist der Umsatz von IV Medications Elsevier?

    Um geschätzte Einnahmen der IV Medications Elsevier-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung

4.5 von 5

4 Bewertungen in Mexiko

5 star
3
4 star
0
3 star
1
2 star
0
1 star
0
Bewertungsverlauf

IV Medications Elsevier Bewertungen

Incorrect brand-generic conversions

Phrexy on

Vereinigte Staaten

Searching and tapping unasyn opens amifostine instead of unasyn. Thankfully this was caught. Edit: search “keppra” and the incorrect generic “lacosamide” comes up. This app is untrustworthy and can longer be used as reference.

Drugs are current and updated

Rustybag on

Vereinigte Staaten

The drug database updates with the actual publishers content. Peace of mind when dealing with newly approved FDA medications.

Unreasonable full access price.

Andichdjay on

Vereinigte Staaten

This app would be great if it wasn’t overpriced. $49.99 seems unreasonably high.

Store-Rankings

Ranking-Verlauf
Kategorien-Rankings
App ist noch nicht gerankt

Schlüsselwörter

IV Medications Elsevier Konkurrenten

Name
Mosby's Drug Reference
Over 5,000 Drug Listings
PEPID®
Davis’s Lab & Diagnostic Tests
with Nursing Implications
Critical- Medical Guide
IV Medications Gahart
#1 IV Reference for Nurses
Nurse's Drug Handbook
Rx pharmacology reference
Micromedex IV Compatibility
RNotes®
Nurse's Clinical Pocket Guide
OmniMedix Medical Calculator
Infusión Calculadora
Bomba de Infusión

IV Medications Elsevier Installationen

Letzte 30 Tage

IV Medications Elsevier Umsatz

Letzte 30 Tage

IV Medications Elsevier Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von IV Medications Elsevier mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.